MLV/George B. Zavoico - init. 2-8-10 Buy/PT=$10, CURR: Buy/$3.50
So why would anyone be excited about this report? First of all I believe the consensus was mgmt knows the astronomical value of pphm and will not sell low and pphm should be worth $100 yet this report only gives a buy target of $3.50?
What is even more alarming is that a buy was initiated in Feb 2010 for a price target of $10 and five years later the price target is $3.50. That is some great buildup of shareholder value by our esteemed mgmt team. It is unexplicable how no one has lost their job, and how the BOD remains at only four people. I guess no one else is allowed in so the secrets doings stay in house for now.
PPHM THE COMPANY THAT HAS BEEN LOOKING TO ADD QUALIFIED BOARD MEMBERS SINCE 2010 YET CAN'T FIND A MATCH WITH THE CURRENT CREDENTIALS OF OUR BOD AND THEIR PENNY STOCK PEDIGREE. 75% OF THE BOARD HAS TIES TO PATRIOTIC SCIENTIFIC WHICH NOW TRADES AT 6 PENNIES YET THE COMPANY CLAIMS TO HAVE AN INDEPENDENT BOD. ALL IMO.
Mar25: Immune Checkpoint Inhibitors (ICI) Forum (designed with Merck, BMS, Genentech, Novartis, EMD-Serono, Amgen), Boston http://tinyurl.com/ktbjn3d …11:30am/Oral-Pres: Jeff Hutchins (VP/PreclinRes), “Expansion & Activation of T-cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Other Checkpoint Inhibitors”
Mar28: Society of Surgical Oncology's 68th Annual Cancer Symposium (SSO 2015), Houston http://tinyurl.com/q667hua …12:45pm/Oral-Pres: Adam C. Yopp (MD/UTSW/Dallas), Ph.2 Data) from Bavi+Sorafenib Liver IST, ”A Phase II Study of Bavituximab & Sorafenib in Advanced Hepatocellular Carcinoma (HCC)”
Apr18-22: AACR 106th Annual Meeting, Phily http://www.aacr.org/2015 http://www.abstractsonline.com/Plan/AdvancedSearch.aspx • Abstract# 274: “Bavituximab Modulates Tumor Microenvironment and Activates CD8+ Tumor Infiltrating Lymphocytes in a Patient-Derived 3D Ex-Vivo System of Lung Cancer” • Abstract# 252: “Antibody-Mediated Phosphatidylserine Blockade Significantly Enhances the Efficacy Of Immune Checkpoint Blockades in K1735 and B16 Mouse Melanoma Models” • Abstract# 4289: “Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances the Activity of Immune Checkpoint Inhibitors in Breast Tumors”
News 
Market Data 
Discover 
